
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
TAP Pharmaceutical Products agreed to settle claims that consumers and private insurers overpaid for the LHRH hormone analog leuprolide acetate (Lupron), according to a report in The Boston Globe.





